PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

tion: Novartis. Thieblemont, C: Honoraria: Gilead, Roche, Cellectis, Celgene; Research Funding: Roche. Ghosh, M: Research Funding: Incyte, Novartis. Riedell, P: Honoraria: Kite Pharma, Bayer, Novartis, Verastem. Yateman, N: Employment Leadership Position: Novartis. Lehnhoff, K: Employment Leadership Position: Novartis. Lawniczek, T: Employment Leadership Position: Novartis. Pacaud, L: Employment Leadership Position: Novartis. Fowler, N: Research Funding: Celgene, Janssen, Abbvie; Other Remuneration: Celgene, Roche, Janssen, Abbvie, TG Therapeutics.